Abstract
The role of the ATP-gated receptor, P2X(7), has been evaluated in the unilateral 6-OHDA rat model of Parkinson's disease using the P2X(7) competitive antagonist A-438079. Nigral P2X(7) immunoreactivity was mainly located in microglia but also in astroglia. A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores. However, this was not associated with a reduction of DA cell loss. Blockade of P2X(7) receptors may represent a novel protective strategy for striatal DA terminals in Parkinson's disease and warrants further future investigation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
3,4-Dihydroxyphenylacetic Acid / metabolism
-
Adrenergic Agents / toxicity
-
Analysis of Variance
-
Animals
-
Brain / metabolism
-
Cell Count / methods
-
Chromatography, High Pressure Liquid / methods
-
Disease Models, Animal
-
Dopamine / metabolism*
-
Glial Fibrillary Acidic Protein / metabolism
-
Homovanillic Acid / metabolism
-
Male
-
Nerve Degeneration / complications
-
Neural Pathways / metabolism
-
Oxidopamine / toxicity
-
Parkinson Disease / complications*
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / etiology
-
Purinergic P2 Receptor Antagonists*
-
Pyridines / therapeutic use*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Purinergic P2 / metabolism*
-
Receptors, Purinergic P2X7
-
Statistics, Nonparametric
-
Tetrazoles / therapeutic use*
Substances
-
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine
-
Adrenergic Agents
-
Glial Fibrillary Acidic Protein
-
P2rx7 protein, rat
-
Purinergic P2 Receptor Antagonists
-
Pyridines
-
Receptors, Purinergic P2
-
Receptors, Purinergic P2X7
-
Tetrazoles
-
3,4-Dihydroxyphenylacetic Acid
-
Oxidopamine
-
Dopamine
-
Homovanillic Acid